Equities

Liaoning Chengda Biotechnology Co Ltd

688739:SHH

Liaoning Chengda Biotechnology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)22.55
  • Today's Change-0.12 / -0.53%
  • Shares traded798.66k
  • 1 Year change-33.01%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5,6976,0806,359
Total Receivables, Net1,0941,113959
Total Inventory422480385
Prepaid expenses302537
Other current assets, total5.008.2757
Total current assets7,2497,7067,798
Property, plant & equipment, net1,9751,6531,441
Goodwill, net------
Intangibles, net542353197
Long term investments225259305
Note receivable - long term------
Other long term assets1.641.711.79
Total assets10,08110,0569,793
LIABILITIES
Accounts payable215140119
Accrued expenses107109118
Notes payable/short-term debt000.00
Current portion long-term debt/capital leases4.864.534.49
Other current liabilities, total302047
Total current liabilities357273289
Total long term debt151722
Total debt202226
Deferred income tax9.504.669.03
Minority interest------
Other liabilities, total101111121
Total liabilities482406441
SHAREHOLDERS EQUITY
Common stock416416416
Additional paid-in capital5,0345,0345,034
Retained earnings (accumulated deficit)4,2484,1993,901
Treasury stock - common(100)----
Unrealized gain (loss)------
Other equity, total------
Total equity9,5999,6509,352
Total liabilities & shareholders' equity10,08110,0569,793
Total common shares outstanding413416416
Treasury shares - common primary issue2.9800
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.